Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 510

1.

Impact of exogenous sequences on the characteristics of an epidemic type 2 recombinant vaccine-derived poliovirus.

Riquet FB, Blanchard C, Jegouic S, Balanant J, Guillot S, Vibet MA, Rakoto-Andrianarivelo M, Delpeyroux F.

J Virol. 2008 Sep;82(17):8927-32. doi: 10.1128/JVI.00239-08. Epub 2008 Jun 25.

2.

Recombination between polioviruses and co-circulating Coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses.

Jegouic S, Joffret ML, Blanchard C, Riquet FB, Perret C, Pelletier I, Colbere-Garapin F, Rakoto-Andrianarivelo M, Delpeyroux F.

PLoS Pathog. 2009 May;5(5):e1000412. doi: 10.1371/journal.ppat.1000412. Epub 2009 May 1.

3.

Circulating vaccine-derived polioviruses: current state of knowledge.

Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizu H, Nathanson N, Pallansch MA.

Bull World Health Organ. 2004 Jan;82(1):16-23. Epub 2004 Feb 26. Review.

4.
5.

Common and diverse features of cocirculating type 2 and 3 recombinant vaccine-derived polioviruses isolated from patients with poliomyelitis and healthy children.

Joffret ML, Jégouic S, Bessaud M, Balanant J, Tran C, Caro V, Holmblat B, Razafindratsimandresy R, Reynes JM, Rakoto-Andrianarivelo M, Delpeyroux F.

J Infect Dis. 2012 May 1;205(9):1363-73. doi: 10.1093/infdis/jis204. Epub 2012 Mar 29.

PMID:
22457288
6.

Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar.

Rakoto-Andrianarivelo M, Gumede N, Jegouic S, Balanant J, Andriamamonjy SN, Rabemanantsoa S, Birmingham M, Randriamanalina B, Nkolomoni L, Venter M, Schoub BD, Delpeyroux F, Reynes JM.

J Infect Dis. 2008 May 15;197(10):1427-35. doi: 10.1086/587694.

PMID:
18419577
7.

Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Shimizu H, Thorley B, Paladin FJ, Brussen KA, Stambos V, Yuen L, Utama A, Tano Y, Arita M, Yoshida H, Yoneyama T, Benegas A, Roesel S, Pallansch M, Kew O, Miyamura T.

J Virol. 2004 Dec;78(24):13512-21.

8.

Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2011 Jul 1;60(25):846-50.

9.

Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.

Famulare M, Chang S, Iber J, Zhao K, Adeniji JA, Bukbuk D, Baba M, Behrend M, Burns CC, Oberste MS.

J Virol. 2015 Oct 14;90(1):317-31. doi: 10.1128/JVI.01532-15.

10.
11.

Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.

Yang CF, Naguib T, Yang SJ, Nasr E, Jorba J, Ahmed N, Campagnoli R, van der Avoort H, Shimizu H, Yoneyama T, Miyamura T, Pallansch M, Kew O.

J Virol. 2003 Aug;77(15):8366-77.

12.

[Eradication of poliomyelitis and emergence of pathogenic vaccine-derived polioviruses: from Madagascar to Cameroon].

Delpeyroux F, Colbère-Garapin F, Razafindratsimandresy R, Sadeuh-Mba S, Joffret ML, Rousset D, Blondel B.

Med Sci (Paris). 2013 Nov;29(11):1034-41. doi: 10.1051/medsci/20132911021. Epub 2013 Nov 20. Review. French.

13.

Update on vaccine-derived polioviruses.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2006 Oct 13;55(40):1093-7.

14.

Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar.

Rakoto-Andrianarivelo M, Guillot S, Iber J, Balanant J, Blondel B, Riquet F, Martin J, Kew O, Randriamanalina B, Razafinimpiasa L, Rousset D, Delpeyroux F.

PLoS Pathog. 2007 Dec;3(12):e191.

15.

Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence.

Combelas N, Holmblat B, Joffret ML, Colbère-Garapin F, Delpeyroux F.

Viruses. 2011 Aug;3(8):1460-84. doi: 10.3390/v3081460. Epub 2011 Aug 17. Review.

16.

Wild poliovirus circulation among healthy children immunized with oral polio vaccine in Antananarivo, Madagascar.

Andrianarivelo MR, Rabarijaona L, Boisier P, Chezzi C, Zeller HG.

Trop Med Int Health. 1999 Jan;4(1):50-7.

17.

Characterization of a rare natural intertypic type 2/type 3 penta-recombinant vaccine-derived poliovirus isolated from a child with acute flaccid paralysis.

Zhang Y, Wang H, Zhu S, Li Y, Song L, Liu Y, Liu G, Nishimura Y, Chen L, Yan D, Wang D, An H, Shimizu H, Xu A, Xu W.

J Gen Virol. 2010 Feb;91(Pt 2):421-9. doi: 10.1099/vir.0.014258-0. Epub 2009 Oct 21.

PMID:
19846676
18.

Implications of a circulating vaccine-derived poliovirus in Nigeria.

Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, Corander J, Garnier S, Chauvin C, Abanida E, Pate MA, Adu F, Baba M, Grassly NC.

N Engl J Med. 2010 Jun 24;362(25):2360-9. doi: 10.1056/NEJMoa0910074. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

19.

Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.

Chowdhary R, Dhole TN.

J Med Virol. 2008 Aug;80(8):1477-88. doi: 10.1002/jmv.21230.

PMID:
18551602
20.

Modeling the dynamics of oral poliovirus vaccine cessation.

Thompson KM, Duintjer Tebbens RJ.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S475-84. doi: 10.1093/infdis/jit845.

PMID:
25316870

Supplemental Content

Support Center